By Ann Leen, Ph.D., Co-Founder and CSO of AlloVir
Serious infections caused by viruses including BK virus, cytomegalovirus (CMV), adenovirus (AdV), and Epstein-Barr virus (EBV) are major causes of morbidity and mortality in transplant patients. These viruses are widespread in the general population but are typically unnoticed or produce no symptoms in healthy people with competent immune systems. However, transplant patients, who require immunosuppressive drug regimens, are highly vulnerable to serious viral infections, which are fatal in up to 20% of patients.1
Some opportunistic viral infections in transplant patients can be treated with off-label antiviral agents such as ganciclovir for CMV. However, not all patients respond to antivirals and their side effects also limit their clinical use. Moreover, antiviral agents do not address the root cause of transplant-associated viral infections: the dearth of virus-specific T cells in immunocompromised patients.
In 1994, an investigational option for these patients appeared on the horizon: adoptively transferred virus-specific T cells (VSTs), which were selectively expanded from stem cell transplant donors. Our group first explored the clinical potential of administering such cells to allogeneic hematopoietic stem cell transplant (HSCT) recipients to prevent and/or treat EBV infections.
Twenty-five years later, VSTs have the potential to offer immunocompromised individuals protection from a multitude of viral infections. Advances in the science and manufacturing of VSTs have enabled the generation of VST lines reactive against multiple clinically problematic viruses up to seven in a development product and six in proof-of-concept studies,2so far that can be prospectively prepared from healthy third-party donors. These advances allow for off-the-shelf use of VSTs to treat large numbers of patients infected with multiple viruses.
Here I recount the major stepping stones on the journey that has brought this exciting field to the threshold of preventing and treating serious viral infections in high-risk populations with T cell deficiencies.
Origins in EBV: 1994-1998
EBV-associated lymphoproliferation is a devastating and potentially fatal disease caused by uncontrolled EBV reactivation. Prior to the 1997 approval of rituximab, the disease occurred in about 10% of transplant patients and there were no effective treatments. In the early 1990s, Dr. Cliona Rooney, an EBV expert, and Dr. Helen Heslop, a physician specializing in HSCT, collaborated on the development of a new approach for the disease: the ex vivo amplification, expansion, and infusion of donor-derived EBV-specific T cells.
In 1994, they reported the successful treatment of EBV-associated lymphoma in an HSCT patient.3Over the next few years, they tested EBV-specific T cells in a total of 114 HSCT patients.4,5None of the patients who were infused prophylactically developed EBV-associated post-transplant lymphoproliferative disease (EBV-PTLD). As a treatment, they were effective in 11 of 13 patients. Of the two patients who did not respond, one had extensive CNS disease and died shortly following infusion; the other had a deletion in the immunodominant EBNA3B gene that abolished the two T cell epitopes recognized by the infused donor VST line, leading to tumor immune escape.
These early studies demonstrated the safety and therapeutic potential of donor-derived VSTs to prevent or treat serious EBV-associated disease in transplant patients.
From One to Many: 1998-2013
Implementation of VST therapies in transplant patients was initially limited by several factors.
First, individualized VST lines had to be prepared for each donor-recipient pair, using a time-consuming and costly manufacturing process that was not readily extendable to a broad patient population.
Second, increasing use of virus-nave stem cell sources such as cord blood, precluded the ex vivo preparation of VSTs.
Third, transplant patients are often infected with multiple viruses, but it was impractical and costly to generate combinations of single virus-specific T cells targeting all viruses in a patient.
These limitations highlighted the need for T cell therapies with specificity for more than one virus (multi-specific VSTs). Preferably, these cells could be generated ahead of time from third-party donors, and provided as a partially HLA-matched product to immunocompromised patients.
The development of VSTs meeting these requirements occurred in two stages. The first involved developing and testing multi-specific VSTs in settings where the same donor provided both the allograft and the T cells (donor-specific).
Our group conducted two clinical trials using donor-derived bi-specific (EBV and AdV) or tri-specific (EBV, AdV, CMV) VSTs, which were prepared by genetically modifying monocytes and EBV-transformed lymphoblastoid cell lines with an empty or CMV-pp65 transgene-expressing adenoviral vector.6,7 These multi-virus VSTs proved safe and effective in allogeneic HSCT recipients; for example, by resolving liver lesions in a patient with EBV-associated lymphoproliferation and treating AdV-induced, drug-refractory pneumonia in a patient on mechanical ventilation.
Going Off-the-Shelf: 2013-2019
Through 2009, the manufacturing process for VSTs required infectious viruses, viral vectors, and intensive, prolonged culture periods that extended over several months. Beginning in 2010, we developed a new manufacturing process that employed a simplified culture technology that excluded all viral components and reduced culture time to 2-3 weeks. This process was used to generate tri-specific VSTs (EBV, CMV, AdV) in a donor-specific setting that proved safe and produced complete responses (CRs) in 10 of 13 HSCT patients, including four with dual infections.8
Meanwhile, as the development of multi-specific VST therapies in the donor-specific setting progressed, we moved into the second stage by investigating the potential of infusing off-the-shelf VSTs prepared from third-party donors to HSCT recipients with refractory viral infections.
In our initial multicenter clinical trial of this approach, we utilized 18 tri-specific VSTs (EBV, CMV, AdV) from a bank of 32 cell lines to treat 50 HSCT patients. The lines infused matched at least one to four (out of six) HLA alleles and were used to treat patients who had infections with one or more of the target viruses that had proven refractory to conventional antivirals. Responses were achieved in patients infected with each of the target viruses. Indeed, complete or partial responses were observed in 17 of 23 CMV patients (73.9%), 14 of 18 AdV patients (77.8%), and 6 of 9 EBV patients (66.7%), and these benefits were durable. Furthermore, responders included patients with established organ disease, such as CMV colitis and EBV-PTLD, as well as those with persistent viremia only. The safety profile of the banked VSTs was also favorable, with only two patients developing de novo graft-versus-host disease (GvHD).9
Having shown that off-the-shelf tri-specific VST therapies were a feasible and safe therapeutic option, the next challenge was generating VSTs specific for more than three viruses.
The VST field began to advance rapidly on several important fronts.
We next incorporated BK virus and human herpesvirus 6 (HHV6) specificity into the cocktail of viruses targeted within our multi-virus product. This novel VST product, posoleucel, which targets 12 antigens from five different viruses BKV, CMV, EBV, AdV and HHV6 was first clinically tested in the donor-specific setting with the administration of VSTs to 11 allogeneic HSCT patients, eight of whom had up to four active viral infections. These VSTs proved safe in all patients and produced a 94% virological and clinical response rate that was sustained long-term.10
This proof-of-concept study paved the way to a larger trial evaluating off-the-shelf use of this multi-virus-targeted T cell therapy. In this study, which was published in 2017, we administered partially matched VSTs to 38 HSCT patients who, between them, had 45 severe or drug-refractory viral infections. The infusions were safe, with just two cases of de novo GvHD, and produced clinical benefit with a cumulative CR/PR rate of 92%.11Importantly, we achieved clinical improvement in 31 patients treated for a single infection, seven patients treated for multiple infections, and in patients with virus-associated diseases, including BK-associated hemorrhagic cystitis.
Today, we have multiple VST products in preclinical and clinical testing, the most advanced of which, posoleucel (formerly Viralym-M; ALVR105), targets six viruses: BKV, CMV, AdV, EBV, HHV-6, and JC virus. Another clinical-stage product, ALVR106, targets multiple antigens from respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV)12to treat HSCT patients and others at high risk from infection with these viruses.
State of the Art
Looking back across a quarter of a century, I am gratified to see how far the VST concept has come: from a labor-intensive boutique therapy that generated one therapy for one virus destined for a single patient to a drug product targeting multiple viruses and accessible to many patients. Two game-changing factors have led to the current VST clinical development path: the feasibility of using VST therapies as an off-the-shelf product for patients with a partial HLA match, and the manufacturing solutions and refinements introduced over the last decade.
Today, I believe VSTs are an example of the right therapy coming into its own at just the right time. For decades, physicians and scientists have recognized the immune systems role as a finely tuned machine that protects us for our entire lives. Over the last 18 months, the Covid-19 pandemic has also educated many lay people about the immune system, engendering an even deeper appreciation of the power of VST therapies to restore patients immune systems and protect them from the devastation of viral infections.
Excerpt from:
25 Years Of VST Therapies The Journey Behind The Technology And Innovation - BioProcess Online
- One year to test 200 Cordlife samples 'totally unjustified': Global cord blood banking experts - The Straits Times - April 15th, 2024
- Clinical trial: First cardiac bioimplants for treatment of myocardial infarction using umbilical cord stem cells - Medical Xpress - April 7th, 2024
- The umbilical cord: a rich and ethical stem cell source to advance ... - March 30th, 2024
- Story of discovery: getting a Notch up on cord blood cell ... - March 30th, 2024
- Cord Blood Transplants | Memorial Sloan Kettering Cancer Center - March 30th, 2024
- Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel ... - Nature.com - March 17th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024: The Vast Majority of the Global Cord Blood Market is Now ... - PR Newswire - March 15th, 2024
- Improving Transplant Outcomes and Cell Therapy Approaches - RegMedNet - March 9th, 2024
- The inhibition of ADAM17 in cord blood stem cell-derived CD16+ NK cells to enhance their cytotoxicity against acute ... - ScienceDirect.com - March 1st, 2024
- Beating Blood Cancer through Recycling - a Community crowdfunding project in Liverpool by Kate Williams - Crowdfunder UK - February 24th, 2024
- Cord Blood Registry (CBR ) by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing - Investing.com Canada - February 9th, 2024
- Young cancer patient with 'no hope' of recovery saved by baby's umbilical cord - Study Finds - February 9th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN - January 26th, 2024
- Finding the optimal combination of anticancer drug administration for the conditioning of cord blood transplantation - Medical Xpress - January 26th, 2024
- Cord Blood Banking Market Sales and Revenue Report 2023-2032 - WhaTech Technology and Markets News - January 26th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN USA - January 24th, 2024
- Global Biobanking Market Size To Exceed USD 97.5 Billion By 2032 | CAGR of 5.8% - GlobeNewswire - January 24th, 2024
- The use of cryopreservation in life saving research - The Manufacturer - January 24th, 2024
- CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies - Medical Xpress - January 18th, 2024
- Cord blood banking comes at a high cost to babies - STAT - STAT - January 18th, 2024
- Global Cord Blood and Tissue Banking Industry Gains Traction Amidst Surging M&A Activity and Technological Advances - PR Newswire - January 16th, 2024
- Donating Bone Marrow and Stem Cells: The Process and What To Expect - On Cancer - Memorial Sloan Kettering - January 11th, 2024
- Ask the doctors: Research being conducted on using stem cells to treat diabetes - The Spokesman Review - January 4th, 2024
- askST: Can cord blood units be transferred from one bank to another? - The Straits Times - December 27th, 2023
- Timeline: Cordlife's mishandling of cord blood units in Singapore - CNA - December 15th, 2023
- Next-Level Evolution: Enhancing the Human Body With Anthrobots ... - Securities.io - December 5th, 2023
- Fred Hutch at ASH: Gene therapies for sickle cell, how to improve ... - Fred Hutchinson Cancer Center - December 5th, 2023
- Enhancing the immunosuppressive properties of human umbilical ... - Phys.org - December 1st, 2023
- Global Status and Trends for Thromboangiitis Obliterans | JPR - Dove Medical Press - December 1st, 2023
- Early Stage Cell Therapy Trial Shows Promise in Treating Progressive Multiple Sclerosis - University of Colorado Anschutz Medical Campus - December 1st, 2023
- Global Medical Specialty Bag Market is Expected to Reach US$ 9.4 Billion by 2034, Rising at a Steady 4.7% CAGR | Future Market Insights, Inc. - Yahoo... - November 29th, 2023
- Repeated concussions can alter heart activity and impact the heart ... - Philippine Canadian Inquirer - November 29th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - PharmiWeb.com - November 27th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - Marketscreener.com - November 25th, 2023
- FY 2021 VA-Funded Projects - VA's Office of Research and Development - November 25th, 2023
- New study aims to expand access to stem cell transplant using ... - Healio - November 23rd, 2023
- Impact of GVHD Prophylaxis on CMV Reactivation and Disease ... - Cancer Network - November 23rd, 2023
- The Top 25 Women Leaders in Biotechnology of 2023 - The Healthcare Technology Report. - November 21st, 2023
- First Edition: November 20, 2023 - KFF Health News - November 21st, 2023
- An essential guide to the building blocks of life - Gates Notes - November 21st, 2023
- A Simple Way to Save Premature Babies - The New York Times - November 19th, 2023
- Perspectives of current understanding and therapeutics of Diamond ... - Nature.com - November 17th, 2023
- Brain Organoids: Should They Be Considered People? - BBVA OpenMind - November 17th, 2023
- Understanding the cause of childhood Alzheimer's - ASBMB Today - November 17th, 2023
- Peripheral nerve regeneration through nanofiber scaffolds | IJN - Dove Medical Press - November 15th, 2023
- Are STEM CELL EXOSOMES the secret to a 'snatched' jawline? Discover the products that influencers are claiming - Daily Mail - November 13th, 2023
- CAR-NK: The next generation in hematological malignancy treatment - News-Medical.Net - November 13th, 2023
- Regenerative Medicine | Top Regenerative Medicine Solution ... - Healthcare Tech Outlook - November 13th, 2023
- Stem cell therapy, emerging solution to slow down ageing - Punch Newspapers - November 13th, 2023
- Improving Cord Blood Transplantation Outcomes for Adults With ... - On Cancer - Memorial Sloan Kettering - November 11th, 2023
- 8 Ways To Save Lives With Canadian Blood Services & You Can ... - Narcity Canada - November 11th, 2023
- Internal investigation by Vita 34 AG reveals irregularities related to a ... - Marketscreener.com - November 11th, 2023
- 'We worried the worst would happen' - Yorkshire Children's Trust ... - The Yorkshire Post - November 11th, 2023
- Minor GPI(-) granulocyte populations in aplastic anemia and healthy ... - Nature.com - November 9th, 2023
- Repeated treatment with ProTrans is immunologically safe ... - Marketscreener.com - November 7th, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells - Benzinga - November 7th, 2023
- Health Canada issues warning on cord blood stored in Edmonton - CBC News - November 3rd, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting - Yahoo... - November 3rd, 2023
- Dynamic Stem Cell Therapy Uncovers Research in Advance ... - InvestorsObserver - November 3rd, 2023
- Go with the flow and achieve hearing restoration - Drug Discovery News - November 3rd, 2023
- Cell Therapy Market to Witness Exponential Growth by 2031 ... - Argyle Report - November 1st, 2023
- Cross-talk between Myeloid and B Cells Shapes the Distinct ... - Cancer Discovery - November 1st, 2023
- Comparison of effects of HucMSCs, exosomes, and conditioned ... - Nature.com - October 28th, 2023
- The structural and functional complexity of the integrative ... - Science - October 28th, 2023
- Global Primary Cells Market to Witness Growth at 11.41% CAGR to ... - GlobeNewswire - October 26th, 2023
- Hma-Qubec celebrates 25 years of giving life in anniversary ad - - The Message - October 26th, 2023
- Improvement of thermal-stability of chondroitinase ABCI immobilized ... - Nature.com - October 26th, 2023
- Sydney Couple Overcomes Sperm Antibody Issue to Welcome Baby - OPP.Today - October 24th, 2023
- New Research Reveals Surprising Issue with Sperm and Fertility - CityLife - October 24th, 2023
- Biobanking Market to Observe Prominent CAGR of 6.10% by 2029 ... - PharmiWeb.com - October 21st, 2023
- TV shows like BBC's Call The Midwife and C4's One Born Every Minute 'are inaccurately depicting childbirth' an - Daily Mail - October 19th, 2023
- Advances in medical and technological research and SCI - Clyde & Co - October 18th, 2023
- Prognostic Value of Hematogones in Patients With Hematopoietic ... - Cureus - October 18th, 2023
- Stem-Cell Therapy: Filling Gaps in Oro-Maxillofacial Region - Cureus - October 18th, 2023
- The neonatal southern white rhinoceros ovary contains oogonia in ... - Nature.com - October 18th, 2023
- OMG: Sperm injury led to rare baby struggle - news.com.au - October 18th, 2023
- Experts Explain how MS Impacts the Eyes and Eye Health - Health Central - October 18th, 2023
- Newly identified stem cells can lure breast cancer to the spine - Science News Magazine - October 15th, 2023
- Cases of HIV cure | aidsmap - aidsmap - October 15th, 2023
- HokUS-10 scoring system predicts the treatment outcome for ... - Nature.com - October 13th, 2023
Recent Comments